Click here to find out more about Boehringer Ingelheim's BI Cares patient assistance program portal.
US Food and Drug Administration. While these anticoagulants carry similar side effects to warfarin, such as risk for gastrointestinal bleeding and intracranial hemorrhage, INR and PT monitoring are not required. How then are providers to gauge the safety and efficacy of the medication in a patient?
How then are providers to gauge the safety and efficacy of the medication in a patient? Can clinicians monitor these medications with the conventional coagulation assays, or are they rendered useless?[1]The effect of both dabigatran and rivaroxaban on commonly used coagulation assays has been ...